Enlivex Therapeutics (NASDAQ:ENLV) Stock Price Up 6.8% – Here’s Why

Enlivex Therapeutics Ltd. (NASDAQ:ENLV)’s stock price was up 6.8% during mid-day trading on Tuesday . The company traded as high as $1.64 and last traded at $1.57. Approximately 504,142 shares traded hands during mid-day trading, an increase of 55% from the average daily volume of 325,877 shares. The stock had previously closed at $1.47.

Analyst Upgrades and Downgrades

Separately, D. Boral Capital reissued a “buy” rating and issued a $13.00 price target on shares of Enlivex Therapeutics in a report on Tuesday, July 29th.

Enlivex Therapeutics Stock Up 6.8%

The firm has a market capitalization of $37.13 million, a PE ratio of -2.38 and a beta of 0.80. The stock has a 50-day moving average price of $1.20 and a 200 day moving average price of $1.08.

Enlivex Therapeutics (NASDAQ:ENLV) last posted its quarterly earnings data on Friday, May 30th. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. As a group, equities analysts predict that Enlivex Therapeutics Ltd. will post -0.7 earnings per share for the current fiscal year.

Institutional Trading of Enlivex Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in ENLV. Two Sigma Securities LLC purchased a new stake in shares of Enlivex Therapeutics in the fourth quarter valued at approximately $26,000. Jane Street Group LLC increased its position in shares of Enlivex Therapeutics by 527.4% in the first quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock valued at $78,000 after buying an additional 67,886 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Enlivex Therapeutics by 112.6% in the fourth quarter. Renaissance Technologies LLC now owns 158,992 shares of the company’s stock valued at $186,000 after buying an additional 84,203 shares in the last quarter. Finally, Millennium Management LLC purchased a new stake in shares of Enlivex Therapeutics in the fourth quarter valued at approximately $742,000. 1.02% of the stock is currently owned by hedge funds and other institutional investors.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.